NASDAQ, RIGL - Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and
is based in South San Francisco. Rigel is a clinical-stage drug development
company that discovers and develops novel, small molecule drugs for the
treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our
goal is to file one new investigative new drug, or IND, application in a
significant indication each year. We have achieved this goal each year beginning
in 2002. Our pioneering research focuses on intracellular signaling pathways and
related targets that are critical to disease mechanisms. Our productivity has
resulted in strategic collaborations with large pharmaceutical partners to
develop and market our product candidates. We have internal product development
programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and
thrombocytopenia, and cancer, as well as partnered product development programs
relating to asthma and cancer. ...
Read SEC Filing on NASDAQ.com »